Tags

Type your tag names separated by a space and hit enter

Ocular findings after allogeneic hematopoietic stem cell transplantation.
Ophthalmology. 2009 Sep; 116(9):1624-9.O

Abstract

OBJECTIVE

To study the incidence, causes, and outcome of major ocular complications in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).

DESIGN

Retrospective, noncomparative, observational clinical study.

PARTICIPANTS

The study included a total of 620 patients who underwent allogeneic HSCT in the period from 1997 to 2007 at King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

INTERVENTION

Allogeneic HSCT.

MAIN OUTCOME MEASURES

Patients with ocular complications were referred to the ophthalmology division for complete ophthalmologic examination, including visual acuity, tonometry, Schirmer test, biomicroscopy, and dilated ophthalmoscopy. Laboratory investigations were performed whenever indicated. The incidence and causes of major ocular complications after allogeneic HSCT were determined. Visual acuity at 1 year after allogeneic HSCT was recorded.

RESULTS

Major ocular complications occurred in 80 (13%) of 620 patients who underwent allogeneic HSCT. There were 36 male patients (45%) and 44 female patients (55%) with a mean age of 29 years and an age range of 9 to 65 years. Prophylaxis for graft-versus-host disease (GVHD) consisted of cyclosporine and methotrexate in 69 patients, and cyclosporine, methotrexate and corticosteroids, or mycophenolate mofetil in 11 patients. The most frequently encountered ocular complications were chronic GVHD, dry eye syndrome without GVHD, corneal ulcers, cataract, glaucoma, cytomegalovirus retinitis, fungal endophthalmitis, and acquisition of allergic conjunctivitis from atopic donors. There was no correlation between the pattern of ocular complications and the transplanted stem cell source. Best-corrected visual acuity (BCVA) at 1 year after transplantation was less than 20/200 in 13 patients (16%), less than 20/50 in 17 patients (21%), and better than 20/50 in 50 patients (63%).

CONCLUSIONS

Ocular complications are common in patients undergoing allogeneic HSCT. Early recognition and prompt treatment are important.

FINANCIAL DISCLOSURE(S)

The author(s) have no proprietary or commercial interest in any materials discussed in this article.

Authors+Show Affiliations

The Eye Center and The Eye Foundation for Research in Ophthalmology, Riyadh, Saudi Arabia. k.tabbara@nesma.net.saNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19729097

Citation

Tabbara, Khalid F., et al. "Ocular Findings After Allogeneic Hematopoietic Stem Cell Transplantation." Ophthalmology, vol. 116, no. 9, 2009, pp. 1624-9.
Tabbara KF, Al-Ghamdi A, Al-Mohareb F, et al. Ocular findings after allogeneic hematopoietic stem cell transplantation. Ophthalmology. 2009;116(9):1624-9.
Tabbara, K. F., Al-Ghamdi, A., Al-Mohareb, F., Ayas, M., Chaudhri, N., Al-Sharif, F., Al-Zahrani, H., Mohammed, S. Y., Nassar, A., & Aljurf, M. (2009). Ocular findings after allogeneic hematopoietic stem cell transplantation. Ophthalmology, 116(9), 1624-9. https://doi.org/10.1016/j.ophtha.2009.04.054
Tabbara KF, et al. Ocular Findings After Allogeneic Hematopoietic Stem Cell Transplantation. Ophthalmology. 2009;116(9):1624-9. PubMed PMID: 19729097.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ocular findings after allogeneic hematopoietic stem cell transplantation. AU - Tabbara,Khalid F, AU - Al-Ghamdi,Ahmad, AU - Al-Mohareb,Fahad, AU - Ayas,Mouhab, AU - Chaudhri,Naeem, AU - Al-Sharif,Fahad, AU - Al-Zahrani,Hazzaa, AU - Mohammed,Said Y, AU - Nassar,Amr, AU - Aljurf,Mahmoud, PY - 2008/12/16/received PY - 2009/04/27/revised PY - 2009/04/27/accepted PY - 2009/9/5/entrez PY - 2009/9/5/pubmed PY - 2009/9/25/medline SP - 1624 EP - 9 JF - Ophthalmology JO - Ophthalmology VL - 116 IS - 9 N2 - OBJECTIVE: To study the incidence, causes, and outcome of major ocular complications in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). DESIGN: Retrospective, noncomparative, observational clinical study. PARTICIPANTS: The study included a total of 620 patients who underwent allogeneic HSCT in the period from 1997 to 2007 at King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. INTERVENTION: Allogeneic HSCT. MAIN OUTCOME MEASURES: Patients with ocular complications were referred to the ophthalmology division for complete ophthalmologic examination, including visual acuity, tonometry, Schirmer test, biomicroscopy, and dilated ophthalmoscopy. Laboratory investigations were performed whenever indicated. The incidence and causes of major ocular complications after allogeneic HSCT were determined. Visual acuity at 1 year after allogeneic HSCT was recorded. RESULTS: Major ocular complications occurred in 80 (13%) of 620 patients who underwent allogeneic HSCT. There were 36 male patients (45%) and 44 female patients (55%) with a mean age of 29 years and an age range of 9 to 65 years. Prophylaxis for graft-versus-host disease (GVHD) consisted of cyclosporine and methotrexate in 69 patients, and cyclosporine, methotrexate and corticosteroids, or mycophenolate mofetil in 11 patients. The most frequently encountered ocular complications were chronic GVHD, dry eye syndrome without GVHD, corneal ulcers, cataract, glaucoma, cytomegalovirus retinitis, fungal endophthalmitis, and acquisition of allergic conjunctivitis from atopic donors. There was no correlation between the pattern of ocular complications and the transplanted stem cell source. Best-corrected visual acuity (BCVA) at 1 year after transplantation was less than 20/200 in 13 patients (16%), less than 20/50 in 17 patients (21%), and better than 20/50 in 50 patients (63%). CONCLUSIONS: Ocular complications are common in patients undergoing allogeneic HSCT. Early recognition and prompt treatment are important. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article. SN - 1549-4713 UR - https://www.unboundmedicine.com/medline/citation/19729097/Ocular_findings_after_allogeneic_hematopoietic_stem_cell_transplantation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0161-6420(09)00485-0 DB - PRIME DP - Unbound Medicine ER -